Cellestia Biotech Ag Is A Clinical Stage Biopharmaceutical Company Based In Baselswitzerlandfounded In 2014The Company Focuses On Developing Innovative Therapies For Autoimmune Diseases And Multi Drug Resistant Cancerscellestia Aims To Address Unmet Medical Needs By Modulating Pathogenic Gene Expression Through Selective Inhibition Of Transcription Factors In The Cell Nucleustheir Mission Is Tocure Incurable Diseasesand Improve The Quality Of Life For Patients With Limited Treatment Options The Lead Candidatecb 103Is Currently In Phase 2 Investigator Initiated Trials For Multi Drug Resistant Cancers And Is Preparing For A Proof Of Concept Study In Graft Versus Host Diseasegvhd Cellestia Also Engages In R&D Partnershipsco Development Agreementsand Licensing Opportunities To Advance Therapies In Oncology And Autoimmune Diseasesthe Company Has Raised Approximately $49 85 Million In Fundingwith Key Investors Including Ppf Group And Fc Capital
